An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Mar 2020 Planned End Date changed from 21 Apr 2023 to 21 Apr 2033.
- 21 Mar 2020 Planned primary completion date changed from 21 Apr 2023 to 21 Apr 2033.
- 21 Mar 2020 Status changed from recruiting to active, no longer recruiting.